These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9469588)

  • 1. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.
    Ness GC; Chambers CM; Lopez D
    J Lipid Res; 1998 Jan; 39(1):75-84. PubMed ID: 9469588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
    Wilcox LJ; Barrett PH; Huff MW
    J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
    Conde K; Roy S; Freake HC; Newton RS; Fernandez ML
    Lipids; 1999 Dec; 34(12):1327-32. PubMed ID: 10652993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of simvaglyzin and atorvaglyzin on the expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase in rat liver.
    Stakhneva EM; Vavilin VA; Ragino YI; Safronova OG; Shintyapina AB; Ivanova MV
    Bull Exp Biol Med; 2013 Nov; 156(1):63-5. PubMed ID: 24319730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
    Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y
    J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
    Dansette PM; Jaoen M; Pons C
    Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
    Telford DE; Edwards JY; Lipson SM; Sutherland B; Barrett PH; Burnett JR; Krul ES; Keller BT; Huff MW
    J Lipid Res; 2003 May; 44(5):943-52. PubMed ID: 12562847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR; Newton RS
    Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
    Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS
    Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
    Bisgaier CL; Essenburg AD; Auerbach BJ; Pape ME; Sekerke CS; Gee A; Wölle S; Newton RS
    J Lipid Res; 1997 Dec; 38(12):2502-15. PubMed ID: 9458274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
    Pocathikorn A; Taylor RR; Mamotte CD
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia.
    Wu N; Sarna LK; Siow YL; O K
    Am J Physiol Regul Integr Comp Physiol; 2011 Mar; 300(3):R635-43. PubMed ID: 21178122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.
    Ji G; Zhao X; Leng L; Liu P; Jiang Z
    Lipids Health Dis; 2011 Jan; 10():23. PubMed ID: 21269482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.
    Argmann CA; Edwards JY; Sawyez CG; O'Neil CH; Hegele RA; Pickering JG; Huff MW
    J Biol Chem; 2005 Jun; 280(23):22212-21. PubMed ID: 15817453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
    Kolyada AY; Fedtsov A; Madias NE
    Hypertension; 2001 Nov; 38(5):1024-9. PubMed ID: 11711492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.
    Parini P; Gustafsson U; Davis MA; Larsson L; Einarsson C; Wilson M; Rudling M; Tomoda H; Omura S; Sahlin S; Angelin B; Rudel LL; Eriksson M
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1200-6. PubMed ID: 18340009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.